Gut Barrier Permeability-α-Synuclein Axis Modulation
Target: CLDN1, OCLN, ZO1, MLCK
Composite Score: 0.533
Price: $0.53▲38.9%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.533
Top 69% of 1374 hypotheses
T5 Contested
Contradicted by evidence, under dispute
B+
0.70
Top 39%
B
0.60
Top 45%
B
0.60
Top 74%
C
0.40
Top 79%
B+
0.70
Top 42%
C+
0.50
Top 61%
C+
0.50
Top 58%
B+
0.70
Top 39%
C+
0.50
Top 68%
B
0.60
Top 46%
Evidence
5 supporting
|
0 opposing
Citation quality: 100%
Debates
1 session
A
Avg quality: 0.89
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Microbial Inflammasome Priming Prevention
Score: 0.653 | Target: NLRP3, CASP1, IL1B, PYCARD
Vagal Afferent Microbial Signal Modulation
Score: 0.621 | Target: GLP1R, BDNF
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.511 | Target: SNCA, HSPA1A, DNMT1
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.480 | Target: TLR4, SNCA
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.427 | Target: AHR, IL10, TGFB1
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.384 | Target: TH, AADC
Description
Dysbiotic bacteria compromise intestinal barrier integrity through zonulin pathway activation, allowing bacterial antigens and α-synuclein oligomers to enter systemic circulation and seed CNS pathology. Targeted tight junction stabilizers could prevent this peripheral-to-central disease propagation.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Dysbiotic Bacteria
E. coli, gram-negative"]
B["LPS Endotoxin
Release"]
C["TLR4 Activation
Inflammatory Signaling"]
D["MLCK Activation
Phosphorylation"]
E["Tight Junction
Disruption"]
F["CLDN1, OCLN, ZO1
Downregulation"]
G["Gut Barrier
Permeability"]
H["alpha-Synuclein
Aggregation"]
I["Vagal Nerve
Transmission"]
J["CNS alpha-Synuclein
Propagation"]
K["Neurodegeneration
Progression"]
L["Tight Junction
Stabilizers"]
M["Probiotic
Intervention"]
A -->|"produces"| B
B -->|"binds"| C
C -->|"activates"| D
D -->|"phosphorylates"| E
E -->|"reduces"| F
F -->|"increases"| G
G -->|"promotes"| H
H -->|"travels via"| I
I -->|"spreads"| J
J -->|"causes"| K
L -->|"stabilizes"| F
M -->|"restores"| A
style A fill:#ef5350
style B fill:#ef5350
style C fill:#ef5350
style D fill:#ef5350
style E fill:#ef5350
style F fill:#ce93d8
style G fill:#ef5350
style H fill:#ef5350
style I fill:#4fc3f7
style J fill:#ef5350
style K fill:#ffd54f
style L fill:#81c784
style M fill:#81c784
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations
5 with PMID
5 medium
Validation: 100%
5 supporting / 0 opposing
✓
For
(5)
(0)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 4CLIN 1GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 5
Macrophage-derived CTSS drives the age-dependent disruption of the blood-CSF barrier. MEDIUM
Claudin-1 interacts with EPHA2 to promote cancer stemness and chemoresistance in colorectal cancer. MEDIUM
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulat… MEDIUM▼
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Streptococcus pneumoniae extracellular vesicles aggravate alveolar epithelial barrier disruption via autophagi… MEDIUM▼
Streptococcus pneumoniae extracellular vesicles aggravate alveolar epithelial barrier disruption via autophagic degradation of OCLN (occludin).
Benvitimod Inhibits IL-4- and IL-13-Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhib… MEDIUM▼
Benvitimod Inhibits IL-4- and IL-13-Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes.
✗ Opposing Evidence 0
No evidence recorded
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 6 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Based on the provided literature on the gut-brain axis and Parkinson's disease, here are 7 novel therapeutic hypotheses:
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Description: Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.
Target gene/protein: SNCA (α-synuclein), HSPA1A (HSP70), DNMT1
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and gaps in the evidence.
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Critical Weaknesses:
- Mechanistic gap: No direct evidence that SCFAs can disaggregate α-synuclein in vivo. The leap from "SCFAs affect epigenetics" to "SCFAs disaggregate α-synuclein" lacks mechanistic validation.
- Blood-brain barrier assumptions: While some SCFAs cross the BBB, their concentrations and stability in brain tissue remain poorly characterized.
- Chaperone specificity: No evidence that SCFA-medi
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
REFINED DRUG DEVELOPMENT FEASIBILITY ASSESSMENT
Based on the additional data retrieved, I'm updating my feasibility rankings with concrete evidence from current research and clinical pipelines.
UPDATED HYPOTHESIS RANKINGS
1. NLRP3 Inflammasome Inhibition (Hypothesis #6)
Feasibility Score: 8/10 ⬆️ Upgraded based on new clinical dataKey Development Update:
- NT-0796 (PMID:40792655, 2025) showing anti-neuroinflammatory effects specifically in PD subjects
- KPT-8602 (PMID:35721113) demonstrating NF-κB/NLRP3 pathway inhibition in PD models
**Immediate Opportunities:
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 1.2%
Volatility
Low
0.0134
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.507 | ▲ 0.9% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.502 | ▲ 3.0% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.487 | ▼ 0.4% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.489 | ▼ 2.0% | 2026-04-12 05:13 | |
| ⚖ | Recalibrated | $0.499 | ▼ 1.1% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.505 | ▲ 1.3% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.498 | ▼ 5.6% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.528 | ▼ 11.9% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.599 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.602 | ▲ 0.3% | 2026-04-04 16:02 | |
| ⚖ | Recalibrated | $0.601 | ▲ 17.5% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.511 | ▼ 19.2% | market_dynamics | 2026-04-03 01:06 |
| ⚖ | Recalibrated | $0.633 | ▲ 26.6% | 2026-04-02 21:55 | |
| 📄 | New Evidence | $0.500 | ▲ 7.3% | market_dynamics | 2026-04-02 19:38 |
| ⚖ | Recalibrated | $0.466 | ▲ 10.4% | market_recalibrate | 2026-04-02 19:14 |
Clinical Trials (5) Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALS
PHASE2
RECRUITING
·
NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED
·
NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN
·
NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
PHASE1
NOT_YET_RECRUITING
·
NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED
·
NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
📚 Cited Papers (55)
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Gastroenterology (2010) · PMID:20685314
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Decrease in paracellular permeability and chemosensitivity to doxorubicin by claudin-1 in spheroid culture models of human lung adenocarcinoma A549 cells.
Biochimica et biophysica acta. Molecular cell research (2018) · PMID:29524521
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Gastroenterology (2010) · PMID:20685314
No extracted figures yet
Alteration of intestinal barrier function during activity-based anorexia in mice.
Clinical nutrition (Edinburgh, Scotland) (2014) · PMID:24290874
No extracted figures yet
Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat.
Journal of psychiatric research (2016) · PMID:27491067
No extracted figures yet
Decrease in paracellular permeability and chemosensitivity to doxorubicin by claudin-1 in spheroid culture models of human lung adenocarcinoma A549 cells.
Biochimica et biophysica acta. Molecular cell research (2018) · PMID:29524521
No extracted figures yet
Co-exposure to boscalid and TiO
NanoImpact (2021) · PMID:33869896
No extracted figures yet
Sinapic Acid Alleviated Inflammation-Induced Intestinal Epithelial Barrier Dysfunction in Lipopolysaccharide- (LPS-) Treated Caco-2 Cells.
Mediators of inflammation (2021) · PMID:34539242
No extracted figures yet
Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation.
BMC cancer (2022) · PMID:35248004
No extracted figures yet
Co-exposure to boscalid and TiO
NanoImpact (2021) · PMID:35559963
No extracted figures yet
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Science translational medicine (2022) · PMID:36542691
No extracted figures yet
The Role of Gut Dysbiosis in the Pathophysiology of Neuropsychiatric Disorders.
Cells (2022) · PMID:36611848
No extracted figures yet
📙 Related Wiki Pages (15)
NES Protein proteinOCLN — Occludin geneMLCK Gene geneSynaptic Biomarkers in Neurodegeneration biomarkerNeuroimaging Biomarkers for Neurodegeneration biomarkerMetabolomic Biomarkers in Neurodegeneration biomarkerExosomal miR-155 in Neurodegeneration biomarkerCell-Free DNA Biomarkers in Neurodegeneration biomarkerDNA Methylation Biomarkers in Neurodegeneration biomarkerExosomal Biomarkers in Neurodegeneration biomarkerLiquid Biopsy in Neurodegeneration biomarkerIL-6 (Interleukin-6) in Neurodegeneration biomarkerBlood-Based Biomarkers for Neurodegeneration biomarkerMDS 2026 — Fluid Biomarker Advances in Neurodegene eventCSF Neurofilament Light Chain (NfL) in Neurodegene biomarker
📓 Linked Notebooks (5)
📓 SciDEX Analysis: 2026 04 01 Gap 20260401 225155
Computational notebook for SDA-2026-04-01-gap-20260401-225155
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …
📓 Gut microbiome dysbiosis and Parkinsons disease -- Rich Analysis Notebook
Gene expression, pathway enrichment, statistical tests for: Gut microbiome dysbiosis and Parkinsons disease
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📊 Resource Economics & ROI
Moderate Efficiency
Resource Efficiency Score
0.58
33.7th percentile (747 hypotheses)
Tokens Used
20,466
KG Edges Generated
16
Citations Produced
34
Cost Ratios
Cost per KG Edge
40.53 tokens
Lower is better (baseline: 2000)
Cost per Citation
818.64 tokens
Lower is better (baseline: 1000)
Cost per Score Point
33940.30 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.058
10% weight of efficiency score
Adjusted Composite
0.591
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Efficiency Price Signals
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-16T20:00 | $0.501 | 0.580 |
Wiki Pages
NES ProteinproteinOCLN — OccludingeneMLCK GenegeneSynaptic Biomarkers in NeurodegenerationbiomarkerNeuroimaging Biomarkers for NeurodegenerationbiomarkerMetabolomic Biomarkers in NeurodegenerationbiomarkerExosomal miR-155 in NeurodegenerationbiomarkerCell-Free DNA Biomarkers in NeurodegenerationbiomarkerDNA Methylation Biomarkers in NeurodegenerationbiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegenerationbiomarkerBlood-Based Biomarkers for NeurodegenerationbiomarkerMDS 2026 — Fluid Biomarker Advances in NeurodegeneeventCSF Neurofilament Light Chain (NfL) in Neurodegenebiomarker
KG Entities (12)
GLP1_receptorNLRP3Parkinsons_diseaseSCFA_productionblood_brain_barriergut_microbiomeinflammasome_complexintestinal_barrierneuroinflammation_pathwayneuroprotectiontight_junction_proteinsvagal_signaling_pathway
Dependency Graph (4 upstream, 4 downstream)
Linked Experiments (10)
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleationvalidation | tests | 0.40Iron Dyshomeostasis in MSA Pathogenesis Experimentvalidation | tests | 0.40Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanismsclinical | tests | 0.40Microbiome-Gut Barrier Signatures in ALS — Experiment Designclinical | tests | 0.40Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Interventionclinical | tests | 0.40Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagationclinical | tests | 0.40Tau Co-Pathology in DLB Clinical Heterogeneityclinical | tests | 0.40SCFA-Mediated Neuroinflammation in Alzheimer's Diseaseclinical | tests | 0.40Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progressclinical | tests | 0.40Parkinson's Disease Subtype Classification — Precision Medicine Approachclinical | tests | 0.40
Related Hypotheses
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.921 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.5 years
🧪 Falsifiable Predictions (2)
2 total
0 confirmed
0 falsified
If hypothesis is true, intervention address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoration compared to either approach alone
pending
conf: 0.60
Expected outcome: address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoration compared to either approach alone
Falsified by: Intervention fails to address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoration compared to either approach alone
If hypothesis is true, intervention sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction
pending
conf: 0.60
Expected outcome: sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction
Falsified by: Intervention fails to sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction
Knowledge Subgraph (7 edges)
associated with (2)
contributes to (1)
encodes component (1)
maintains (1)
mediates (1)
promotes (1)
Mechanism Pathway for CLDN1, OCLN, ZO1, MLCK
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
NLRP3["NLRP3"] -->|encodes component| inflammasome_complex["inflammasome_complex"]
neuroinflammation_pathway["neuroinflammation_pathway"] -->|contributes to| Parkinsons_disease["Parkinsons_disease"]
GLP1_receptor["GLP1_receptor"] -->|mediates| vagal_signaling_pathway["vagal_signaling_pathway"]
vagal_signaling_pathway_1["vagal_signaling_pathway"] -->|promotes| neuroprotection["neuroprotection"]
tight_junction_proteins["tight_junction_proteins"] -->|maintains| intestinal_barrier["intestinal_barrier"]
gut_microbiome["gut_microbiome"] -->|associated with| SCFA_production["SCFA_production"]
SCFA_production_2["SCFA_production"] -->|associated with| blood_brain_barrier["blood_brain_barrier"]
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style inflammasome_complex fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_pathway fill:#81c784,stroke:#333,color:#000
style Parkinsons_disease fill:#ef5350,stroke:#333,color:#000
style GLP1_receptor fill:#4fc3f7,stroke:#333,color:#000
style vagal_signaling_pathway fill:#81c784,stroke:#333,color:#000
style vagal_signaling_pathway_1 fill:#81c784,stroke:#333,color:#000
style neuroprotection fill:#ffd54f,stroke:#333,color:#000
style tight_junction_proteins fill:#4fc3f7,stroke:#333,color:#000
style intestinal_barrier fill:#4fc3f7,stroke:#333,color:#000
style gut_microbiome fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production_2 fill:#4fc3f7,stroke:#333,color:#000
style blood_brain_barrier fill:#4fc3f7,stroke:#333,color:#000
3D Protein Structure
🧬 CLDN1 — PDB 5OY6 Click to expand 3D viewer
Source Analysis
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!